Gent, Belgium/July 2021:Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO), in partnership with GHO Capital, announced today a major €35 million investment for expansion across its European operations.
The investment will future proof offerings for the biopharma and emerging biotechnology sectors and positions Ardena to become a leading global CDMO, offering end-to-end solutions spanning the full pharma development lifecycle.
Ardena will significantly expand drug product services in Belgium and aseptic fill and finish capabilities for the development and clinical production of small molecule, injectable formulations. Capacity for large molecule biologics will expand to includePeptides,Oligonucleotides (DNA, recombinant RNA, synthetic RNA, RNA vaccines)andProteins.
This will provide clients with a full-service solution fromformulation development, analytical method development and validation, demo batch production, stability studies, GMP batch production, QC testing,labelling and randomization, QP release, storage and shipping through to regulatory support.
The Swedish facility will undergo expansionto support the commercialization ofCOVID-19 vaccinesand further growth of the API business. This will enable more preparative chromatographyandHPLC andfurther expansion of advanced and specialized filtration technology along withlyophilizationcapacity for bulk quantities.
The investment program will see major improvements in the Netherlands facility, continuing the growth of the API and Nanomedicine activities. This will include theexpansion of cleanroom space (Grade D and C), chemical manufacturing capacity, warehouse space, adding chemistry and analytical labs and investing in new technologies to support Ardena’s leadership in Nanotechnology.
“The significant investment in our expansion is a result of our continued outperformance of the market,” said Harry Christiaens, Ardena CEO. “Our focus on the exciting world of early phase development at an international level has proven to be highly successful. We have a great deal of scientific expertise and will continue to invest in the people and resources we need to deliver for our clients.”
“This an exciting time to be at Ardena,” explained Gerjan Kemperman, Ardena COO. “We have the international experience and network to expertly manage multiple projects, whatever the demands of the market or the technologies required.”
Notes to Editors:
About Ardena Group
The Ardena Group (’Ardena’) is a world-class Contract Development and Manufacturing Organization. Ardena assists pharmaceutical companies, from virtual biotech to big pharma, in bringing their valued molecules to the clinic and the market.
Ardena provides a comprehensive range of services from early drug substance development to finished dosage form, including: drug substance development & manufacturing; solid state research; drug product development & manufacturing; drug product packaging, labelling & supply; bioanalysis; dossier development and nanomedicine. For more information, please visit https://ardena.com/
About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com/